THR.BR : Summary for THROMBOGENICS - Yahoo Finance

U.S. Markets closed

ThromboGenics NV (THR.BR)


Brussels - Brussels Delayed Price. Currency in EUR
Add to watchlist
2.64-0.01 (-0.38%)
At close: 11:35 AM EST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.65
Open2.65
Bid2.96 x 10000
Ask3.01 x 500000
Day's Range2.64 - 2.68
52 Week Range2.59 - 4.03
Volume6,684
Avg. Volume17,957
Market Cap95.29M
BetaN/A
PE Ratio (TTM)-2.51
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswirelast month

    ThromboGenics Business Update - Q3 2016

    LEUVEN, Belgium, October 20, 2016 /PRNewswire/ -- - Diabetic Eye Disease clinical and pre-clinical programs on track   - New Ophthalmic Research presented at EURETINA , EVER and AAO   - Company Q3 2016 ...

  • PR Newswire2 months ago

    Latest ThromboGenics' Clinical Data to be Presented at 2016 American Academy of Ophthalmology (AAO) Meeting in Chicago

    ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, today announces that the company will be attending the upcoming American Academy of Ophthalmology (AAO) 2016 meeting in Chicago, as well as the Subspecialty Day meeting and the Ophthalmology Innovation Summit (OIS@AAO) preceding the official start of the AAO gathering. During AAO, a number of communications - posters, presentations and debates - will report on the large amount of ocriplasmin real world clinical data gathered since its first introduction in 2013, as well as on the outcome of the OASIS study, a 2-year randomized, sham-controlled trial evaluating efficacy and safety of ocriplasmin in 220 patients.

  • PR Newswire3 months ago

    ThromboGenics Presenting New Ophthalmic Research Data

    LEUVEN, Belgium, September 7, 2016 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a Belgium-based biopharmaceutical company developing novel medicines for back of the eye disease, with a focus ...